These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22156451)

  • 1. Well-differentiated hand liposarcoma with bone metastases treated successfully with zoledronic Acid.
    Mystakidou K; Panagiotou I; Brountzos E; Kouloulias V; Gouliamos A
    Onkologie; 2011; 34(12):706-9. PubMed ID: 22156451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Well-differentiated hand liposarcoma with bone metastases treated successfully with zoledronic acid: a molecular mechanism.
    Namazi H
    Onkologie; 2012; 35(5):300. PubMed ID: 22868513
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of zoledronic acid in pediatric cancer patients.
    August KJ; Dalton A; Katzenstein HM; George B; Olson TA; Wasilewski-Masker K; Rapkin LB
    Pediatr Blood Cancer; 2011 Apr; 56(4):610-4. PubMed ID: 21298747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series.
    Montella L; Addeo R; Palmieri G; Caraglia M; Cennamo G; Vincenzi B; Guarrasi R; Mamone R; Faiola V; Frega N; Capasso E; Maiorino L; Leopardo D; Pizza C; Montesarchio V; Del Prete S
    Cancer Chemother Pharmacol; 2010 May; 65(6):1137-43. PubMed ID: 19760218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
    Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
    Miwa S; Mizokami A; Konaka H; Izumi K; Nohara T; Namiki M
    Jpn J Clin Oncol; 2009 Nov; 39(11):745-50. PubMed ID: 19808839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer.
    Hirsh V
    Clin Lung Cancer; 2009 Jul; 10(4):223-9. PubMed ID: 19632938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
    Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
    Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
    Saad F; McKiernan J; Eastham J
    Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid.
    Mountzios G; Terpos E; Syrigos K; Papadimitriou C; Papadopoulos G; Bamias A; Mavrikakis M; Dimopoulos MA
    Transl Res; 2010 May; 155(5):247-55. PubMed ID: 20403580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
    Saad F; Chen YM; Gleason DM; Chin J
    Clin Genitourin Cancer; 2007 Sep; 5(6):390-6. PubMed ID: 17956712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
    Nagao S; Hattori N; Fujitaka K; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Haruta Y; Murai H; Kohno N
    Hiroshima J Med Sci; 2011 Mar; 60(1):7-9. PubMed ID: 21675041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
    Oh WK; Proctor K; Nakabayashi M; Evan C; Tormey LK; Daskivich T; Antràs L; Smith M; Neary MP; Duh MS
    Cancer; 2007 Mar; 109(6):1090-6. PubMed ID: 17311345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
    Berenson JR; Vescio RA; Rosen LS; VonTeichert JM; Woo M; Swift R; Savage A; Givant E; Hupkes M; Harvey H; Lipton A
    Clin Cancer Res; 2001 Mar; 7(3):478-85. PubMed ID: 11297237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
    Lein M; Wirth M; Miller K; Eickenberg HU; Weissbach L; Schmidt K; Haus U; Stephan C; Meissner S; Loening SA; Jung K
    Eur Urol; 2007 Nov; 52(5):1381-7. PubMed ID: 17321667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.